Trial Condition(s):
Multiple Sclerosis
RETAIN: Real world Evidence assessment of inTerferon beta-1b Adherence using autoINjectors (RETAIN)
Bayer Identifier:
20750
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Primary objective(s):
• To describe medication possession ratio (MPR) and persistence rates over the 24-month period prior to (pre-BETACONNECT) and the 24-month period following the introduction and uptake of the BETACONNECT device (post-BETACONNECT) for patients with MS using Betaseron or Rebif.
Secondary objective(s):
• To describe baseline demographic and clinical characteristics in the populations of interest.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
1216
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
Status
| Locations | Status | |
|---|---|---|
Locations Investigative Site Many locations, United States | Status Completed | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
For details, please refer to trial results
Additional Information
Not Available
Copyright © Bayer
Powered by
